logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN

Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer

 

The study by the Genekor Scientific Team on "Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer" was presented at the San Antonio Breast Cancer Symposium 2022 in the form of a Poster.

Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer

The study by the Genekor Scientific Team on "Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer" was presented at the San Antonio Breast Cancer Symposium 2022 in the form of a Poster.

 

The Polygenic Risk Score is a tool used to identify and calculate the lifetime risk of breast cancer, and we are therefore investigating whether it can be used in a cohort of 105 patients to identify this risk.

 

The conclusions reached by the Genekor scientific team are:

  • PRS can asssit in the estimation of risk of developing  breast cancer in approximately 30% of the people who are negative in genetic testing.
  • Jointly, pathogenic alteration in high and  intermediate risk genes (20%) and PRS (30%) is  estimated to justify 50% of women with risk of  developing breast cancer
  • PRS does not seem to be able to assist in the  improvement of the estimation of the risk in carriers  of alterations in intermediate-risk genes but it helps  in low-risk genes.

 

 To read the poster click here.

 

 

 

 

15.12.2022
Change cookies consent Revoke cookies consent